Millions of Brits Turn to GLP-1 Medications for Weight Loss

A recent study reveals that approximately 4.9 million adults in the United Kingdom are using or considering glucagon-like peptide-1 (GLP-1) or dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) medications to assist with weight loss. This finding, published in BMC Medicine, is based on a survey of 5,260 British adults conducted between January and March 2025. The results indicate a significant interest in these medications, which are known to help lower blood sugar, promote weight loss, and mitigate risks associated with heart and kidney complications.

The medications liraglutide, semaglutide, and tirzepatide are currently approved for weight loss in the UK. However, it is estimated that only around 220,000 individuals will qualify for treatment through the National Health Service (NHS) between 2025 and 2028. The research team, led by Sarah Jackson, found that 2.9% of participants reported using GLP-1 or GLP-1/GIP medications for weight loss in the past year. Notably, among those not currently using these medications, 6.5% expressed interest in utilizing them within the next year.

Growing Demand and Demographic Insights

Extrapolating from the survey data, Jackson and her colleagues estimate that around 1.6 million British adults may have used GLP-1 or GLP-1/GIP medications for weight loss between 2024 and early 2025, with another 3.3 million showing interest at the beginning of 2025. Among those who used these medications in the past year, 15% reported using a product not licensed for weight loss in the UK, a situation possibly arising from off-label prescribing or online purchases.

The study also highlighted demographic trends, revealing that the use and interest in GLP-1 medications were particularly pronounced among women, individuals aged 45 to 55, and those experiencing moderate to severe psychological distress in the preceding month. Additionally, interest was notably higher among people facing financial difficulties and those not working due to long-term illness or disability.

Implications for Healthcare and Recommendations

These findings underscore a substantial demand for GLP-1 and GLP-1/GIP medications in the UK. The authors advocate for ongoing monitoring of these medications’ usage, health outcomes, and their broader impact on the healthcare system. They emphasize the importance of ensuring these treatments are provided in a manner that is safe, appropriate, sustainable, and equitable.

The research provides crucial insights that could inform healthcare policy and resource allocation as the demand for weight loss medications continues to rise. As the healthcare landscape evolves, understanding the implications of this growing interest will be essential for managing health outcomes effectively.

For further details, refer to the study by Jackson et al. published in BMC Medicine, DOI: 10.1186/s12916-025-04528-7.